Nuvation Bio Inc (NYSE: NUVB) on Friday, plunged -1.71% from the previous trading day, before settling in for the closing price of $2.34. Within the past 52 weeks, NUVB’s price has moved between $1.54 and $3.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -49.14%. The company achieved an average annual earnings per share of 69.19%. With a float of $228.13 million, this company’s outstanding shares have now reached $336.84 million.
Considering the fact that the conglomerate employs 220 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 27.54%, operating margin of -1564.86%, and the pretax margin is -1413.43%.
Nuvation Bio Inc (NUVB) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Nuvation Bio Inc is 33.54%, while institutional ownership is 49.17%. The most recent insider transaction that took place on Jun 18 ’25, was worth 17,100. In this transaction CHIEF PEOPLE OFFICER of this company bought 10,000 shares at a rate of $1.71, taking the stock ownership to the 29,591 shares. Before that another transaction happened on Jun 17 ’25, when Company’s Chief Financial Officer bought 4,000 for $1.79, making the entire transaction worth $7,160. This insider now owns 9,902 shares in total.
Nuvation Bio Inc (NUVB) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.12 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.1) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 38.33% during the next five years compared to -49.14% drop over the previous five years of trading.
Nuvation Bio Inc (NYSE: NUVB) Trading Performance Indicators
Nuvation Bio Inc (NUVB) is currently performing well based on its current performance indicators. A quick ratio of 9.38 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 54.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.63, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Nuvation Bio Inc (NUVB)
Compared to the last year’s volume of 4.19 million, its volume of 3.95 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 26.20%.
During the past 100 days, Nuvation Bio Inc’s (NUVB) raw stochastic average was set at 62.30%, which indicates a significant increase from 19.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.17 in the past 14 days, which was higher than the 0.17 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.21, while its 200-day Moving Average is $2.31.
